Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience

MLA

Maria Bernardetta Aloi, et al. “Impact of Second-Line Treatment (2L T) in Advanced Pancreatic Cancer (APDAC) Patients (Pts) Receiving First Line Nab-Paclitaxel (Nab-P) + Gemcitabine (G): An Italian Multicentre Real Life Experience.” Journal of Clinical Oncology, vol. 34, May 2016, p. 4124. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5b971e5ed08af5d71c42d53fe69ee7e9&authtype=sso&custid=ns315887.

APA

Maria Bernardetta Aloi, Mariacristina Di Marco, Francesca Bergamo, A. Iop, Paola Bertocchi, Vittorina Zagonel, Antonio Febbraro, Gianna Musettini, Giovanni Re, Alberto Zaniboni, Davide Melisi, Guido Giordano, Ferdinando De Vita, Enrico Vasile, Alessandro Passardi, Elisa Giommoni, Michele Milella, Luisa Foltran, Vanja Vaccaro, & Silvia Vecchiarelli. (2016). Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience. Journal of Clinical Oncology, 34, 4124.

Chicago

Maria Bernardetta Aloi, Mariacristina Di Marco, Francesca Bergamo, A. Iop, Paola Bertocchi, Vittorina Zagonel, Antonio Febbraro, et al. 2016. “Impact of Second-Line Treatment (2L T) in Advanced Pancreatic Cancer (APDAC) Patients (Pts) Receiving First Line Nab-Paclitaxel (Nab-P) + Gemcitabine (G): An Italian Multicentre Real Life Experience.” Journal of Clinical Oncology 34 (May): 4124. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........5b971e5ed08af5d71c42d53fe69ee7e9&authtype=sso&custid=ns315887.